X0508 4 2025-11-10 0001133416 GALECTIN THERAPEUTICS INC GALT 0001266773 CALLICUTT JACK W C/O GALECTIN THERAPEUTICS INC. 4960 PEACHTREE INDUSTRIAL BLVD., STE 240 NORCROSS GA 30071 false true false false Chief Financial Officer true Common stock 2025-11-10 4 M false 1880 1.98 A 9694 D Common stock 2025-11-10 4 S false 1880 6.022 D 7614 D Common stock 2025-11-10 4 M false 1675 1.11 A 9289 D Common stock 2025-11-10 4 S false 1675 6.0266 D 7614 D Common stock 2025-11-10 4 M false 1736 1.23 A 9350 D Common stock 2025-11-10 4 S false 1736 6.0298 D 7614 D Stock option (right to buy) 1.98 2025-11-10 4 M false 1880 0 D 0022-06-30 2032-01-24 Common stock 1880 37706 D Stock option (right to buy) 1.11 2025-11-10 4 M false 1675 0 D 2023-06-30 2034-01-26 Common stock 1675 37891 D Stock option (right to buy) 1.23 2025-11-10 4 M false 1736 0 D 2025-06-30 2035-01-22 Common stock 1736 51073 D The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Jack W. Callicutt 2025-11-12